- Home
- PYXS vs CGTX Comparison
PYXS vs CGTX Comparison
Compare PYXS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYXS | CGTX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 94.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PYXS | CGTX |
|---|---|---|
| Price | $1.69 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $7.00 | $3.33 |
| AVG Volume (30 Days) | 338.6K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.03 | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,043.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $0.22 |
| 52 Week High | $5.55 | $3.83 |
Technical Indicators
Market Signals| Indicator | PYXS | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 57.81 |
| Support Level | $1.28 | $1.01 |
| Resistance Level | $1.69 | $1.19 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 71.68 | 88.43 |
Price Performance
Historical ComparisonAbout PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.